Human Ovarian Tumors Express γ-Glutamyl Transpeptidase

Gamma-glutamyl transpeptidase (GGT) is a cell surface enzyme that initiates the cleavage of extracellular glutathione, thereby providing the cell with the amino acids necessary for increased synthesis of glutathione. GGT is induced in ovarian tumor cell lines selected in vitro for resistance to cisplatin. No study has examined GGT expression in primary human ovarian tumors. We analyzed frozen sections of 80 normal human ovaries and 56 ovarian tumors for expression of GGT. Histochemical staining showed that GGT was not expressed in the cells of the follicle or surface germinal epithelium of the normal ovary. GGT was expressed in some epithelial inclusion glands and occasionally in a small subset of stromal cells. Granulosa-stromal cell tumors were largely GGT-negative. In contrast, GGT-positive neoplastic cells were observed in 33 of 45 common epithelial ovarian tumors. None of the patients had been treated with chemotherapy. Some of the tumors had only rare GGT-positive cells, while others consisted almost entirely of GGT-positive cells. Among the low malignant potential and invasive tumors, at least one-half of the cells were GGT-positive in 6 of 9 serous borderline tumors (2 with mucinous foci), 0 of 1 borderline mucinous tumor, 3 of 12 serous papillary carcinomas, 2 of 3 mucinous carcinomas, 1 of 2 endometrioid carcinomas, 2 of 2 clear cell carcinomas, 0 of 2 transitional cell carcinomas, and 4 of 5 undifferentiated carcinomas. There was no correlation between the stage of the tumor and GGT expression, indicating that a GGT-negative tumor does not become GGT-positive as it progresses to a more widely disseminated lesion. In addition, there was no correlation between serum levels of CA 125 and GGT expression. These data show that GGT is expressed in many common ovarian epithelial neoplasms. We are currently following the response of these patients to chemotherapy to determine if expression of GGT serves as a marker for identifying neoplasms with enhanced resistance to platinum-based therapy.

[1]  W. Ricketts,et al.  Extracellular glutathione is a source of cysteine for cells that express gamma-glutamyl transpeptidase. , 1993, Biochemistry.

[2]  S. Pacini,et al.  Altered metabolism of glutathione in cells transformed by oncogenes which cause resistance to ionizing radiations , 1993, FEBS letters.

[3]  R. Berkowitz,et al.  Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. , 1993, Cancer research.

[4]  A. Godwin,et al.  High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[5]  R. Ozols,et al.  Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results. , 1992, Journal of the National Cancer Institute.

[6]  B. Sikic,et al.  Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. , 1991, Cancer research.

[7]  D. Macdonald,et al.  Gamma glutamyl transpeptidase expression in foetal skin, inflammatory dermatoses and cutaneous neoplasia , 1991, The British journal of dermatology.

[8]  N. Ordóñez,et al.  Transitional cell carcinoma in high‐grade high‐stage ovarian carcinoma. An indicator of favorable response to chemotherapy , 1989, Cancer.

[9]  C. Wolf,et al.  Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects. , 1988, Carcinogenesis.

[10]  N. Thompson,et al.  Growth in culture and tumorigenicity after transfection with the ras oncogene of liver epithelial cells from carcinogen-treated rats. , 1987, Cancer research.

[11]  S. Sinha,et al.  Transformation of a rat liver cell line: neoplastic phenotype and regulation of gamma glutamyl transpeptidase in tumour tissue. , 1987, Cancer letters.

[12]  R. Bast,et al.  Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas. , 1986, Cancer research.

[13]  H. Pitot,et al.  Gamma-glutamyl transpeptidase--its role in hepatocarcinogenesis. , 1985, Carcinogenesis.

[14]  A. Blaustein,et al.  Tumor markers in inclusion cysts of the ovary , 1982, Cancer.

[15]  A. Meister,et al.  Serine-borate complex as a transition-state inhibitor of gamma-glutamyl transpeptidase. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A. Meister,et al.  Regulation of gamma-glutamyl-cysteine synthetase by nonallosteric feedback inhibition by glutathione. , 1975, The Journal of biological chemistry.

[17]  G. Glenner,et al.  HISTOCHEMICAL DEMONSTRATION OF A GAMMA-GLUTAMYL TRANSPEPTIDASE-LIKE ACTIVITY , 1962 .

[18]  H. Warenius,et al.  Cellular glutathione (GSH) and glutathione S-transferase (GST) activity in human ovarian tumor biopsies following exposure to alkylating agents. , 1992, International journal of radiation oncology, biology, physics.

[19]  P. Mistry,et al.  Historical aspects of glutathione and cancer chemotherapy. , 1991, Pharmacology & therapeutics.

[20]  J. Findlay.  The ovary. , 1991, Bailliere's clinical endocrinology and metabolism.

[21]  A. Fojo,et al.  Mechanisms of resistance to cisplatin and alkylating agents. , 1989, Cancer treatment and research.

[22]  M. Lieberman,et al.  Two genes associated with liver cancer are regulated by different mechanisms in rasT24 transformed liver epithelial cells. , 1989, Oncogene.

[23]  A. Seligman,et al.  Histochemical and ultrastructural demonstration of gamma-glutamyl transpeptidase activity. , 1969, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.